Pulse Bio COO Buys Above Analyst Target at All-Time High
Pulse Biosciences COO bought nearly $200K of stock above analyst targets as shares hit all-time highs, signaling conviction in the company's cardiac catheter program. The timing suggests management ex
Pulse Bio COO Buys Above Analyst Target at All-Time High
NEW YORK, September 6 —
Pulse Biosciences, Inc. (PLSE) COO Liane Teplitsky spent nearly $200,000 buying stock on four consecutive days at prices above the $45.25 analyst consensus, as shares hit a new all-time high. The purchases sit uneasily against $434,000 in quarterly revenue, a $24.7 million GAAP loss, and a $3.80 billion market cap resting on clinical programs with zero cardiac product revenue.
- Q2 2026 revenue was $434K, all from Vybrance disposables; cardiac catheter and surgical clamp programs generate no commercial revenue.
- Q2 GAAP net loss was $24.7M; Q2 operating cash outflow was $18.7M, up from $14.6M in Q1 2026.
- PLSE trades at $53.24, roughly 18% above the $45.25 analyst consensus; insider ownership is 71% of shares outstanding.
Conviction at a Premium
Teplitsky made four open-market purchases between August 26 and September 1, per Form 4 filings, paying between $48.23 and $49.95 per share, above what the analyst community collectively prices the stock. Insider ownership stands at 71% of shares outstanding, so this was not a new bet but an existing one being enlarged at the high. Short interest represents 13% of the float, meaning the COO was adding into a contested name at record prices. The implicit thesis in those purchases: that NANOPULSE-AF enrollment completing in early October is a repricing event, not a procedural milestone, and that the current price underweights that outcome.
What the Catheter Program Costs
Pulse Biosciences develops the nPulse brand of nanosecond pulsed field ablation devices, which deliver ultrashort, high-voltage pulses to targeted tissue without thermal damage. The only revenue-generating product is the Vybrance percutaneous electrode system for soft-tissue and thyroid ablation; the nPulse Cardiac Catheter and Cardiac Surgical Clamp are pre-commercial. Trailing twelve-month free cash flow was negative $34 million, and running that figure through a DCF calculator illustrates how much terminal-value assumption the current $3.80 billion market cap requires. The company raised $57.5 million through ATM equity sales since May, including a new $75 million ATM facility filed August 6, keeping cash at $101.6 million at quarter-end.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PLSE | $3.8B | n/a | +254.0% |
| PTGX | $9.4B | n/a | +159.3% |
| KIDS | $585M | n/a | +7.2% |
| CUE | $199M | n/a | +17.7% |
| AXGN | $2.6B | 69.6x | +201.0% |
| VRCA | $91M | n/a | +4.7% |
What October Enrollment Decides
The near-term checkpoint is NANOPULSE-AF enrollment, with 82 evaluable patients across 12 sites already enrolled against an expanded target of 164, expected to close in early October, three months ahead of schedule. European feasibility data showed 100% freedom from atrial fibrillation at six months among 95 patients in the five-second ablation cohort and 96% at one year among 53, with a 1.7% serious adverse-event rate. Management targets CE mark submission in the second half of 2026 and European approval around mid-2027. Whether those timelines hold determines whether the COO's premium was prescient or premature. Run the free Pulse Biosciences, Inc. deep-dive for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Pulse Biosciences COO buy stock?
COO Liane Teplitsky spent nearly $200,000 buying stock between August 26 and September 1, paying $48-$50 per share above the $45.25 analyst consensus. The implicit thesis is that NANOPULSE-AF enrollment completing in early October is a repricing event.
What is Pulse Biosciences quarterly revenue?
Q2 2026 revenue was $434,000, all from Vybrance disposables. The company's cardiac catheter and surgical clamp programs currently generate no commercial revenue.
What is NANOPULSE-AF trial?
NANOPULSE-AF is Pulse Biosciences' clinical trial for its nPulse Cardiac Catheter program, testing nanosecond pulsed field ablation for atrial fibrillation. European feasibility data showed 100% freedom from AFib at six months among patients in the five-second ablation cohort.
What is Pulse Biosciences market cap?
Pulse Biosciences' market cap is approximately $3.80 billion at the current trading price of $53.24. This represents an 18% premium above the $45.25 analyst consensus price target.
How much insider ownership does PLSE have?
Insider ownership at Pulse Biosciences stands at 71% of shares outstanding. Short interest represents 13% of the float, indicating significant insider conviction in the company.
Pulse Biosciences' COO spent nearly $200,000 buying stock at prices above the analyst consensus target as shares hit all-time highs — a signal of insider conviction that sits uneasily against a $3.80 billion market cap anchored to $434,000 in quarterly revenue and a $24.7 million quarterly loss.